View More Recent Stories
-
CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment
-
CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC
-
CNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe Forum
-
CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement
-
Maxim Group Upgrades CNS Pharmasceuticals Inc. (CNSP) to Buy, 'Berubicin Glioblastoma Data is Coming into View'
-
CNS Pharmaceuticals (CNSP) Shares Gain 20% Premarket on Maxim Upgrade to Buy
-
CNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
-
CNS Pharmaceuticals to Participate in at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
-
CNS Pharmaceuticals Reports Second Quarter 2024 Financial Results
-
CNS Pharmaceuticals (CNSP) Adds Late Stage, Novel Potential Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies
-
CNS Pharmaceuticals Expands Pipeline with In-License of Late Stage, Novel Potential Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies
-
CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the 2024 SNO/ASCO CNS Cancer Conference
-
CNS Pharmaceuticals to Participate in the Virtual Investor Closing Bell Series
-
CNS Pharmaceuticals (CNSP) Files for up to 2.4M Share Offering by Selling Stockholders
-
CNS Pharmaceuticals (CNSP) Prices 1.425M Share Offering at $1.39/sh
-
CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement
-
CNS Pharmaceuticals (CNSP) Prices Share and Warrant Offering at $2.45/sh
-
CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement
-
CNS Pharmaceuticals (CNSP) Prices Registered Direct Offering and Concurrent Private Placement
-
CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement
